Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China’s First SSTR4 Agonist Targeting Pain

GUANGZHOU, China, Jan. 17, 2025 /PRNewswire/ — Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4. FZ002-037 is a highly selective oral…